Please assess the completion status of the following clinical trial:

Trial Title: Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed inoperable and/or metastatic adenocarcinoma of the oesophagogastric junction or stomach~2. Progression of a measurable lesion (RECIST) on previous palliative chemotherapy. Neoadjuvant/adjuvant treatment is not counted, unless progression occurs \< 6 months after completion of the treatment. In these cases, neoadjuvant/adjuvant treatment is counted as one line.~3. Male and female patients aged \> 18 years~4. ECOG ≤ 1~5. neutrophils ≥ 1500/µl~6. Haemoglobin ≥ 9 g/dl~7. Platelets ≥ 100,000/µl~8. AST/SGOT and/or ALT/SGPT ≤2.5 x ULN;~9. Total bilirubin ≤1.0 x ULN~10. Serum creatinine ≤ 1.5 times the normal value, or creatinine clearance ≥ 60 ml/min~11. Written patient informed consent~Exclusion Criteria:~1. A history of severe hypersensitivity to taxanes (≥ grade 3) or to medicinal products containing polysorbate 80 (≥ grade 3)~2. Active CAD, cardiomyopathy or NYHA stage III-IV heart failure~3. Malignant secondary disease dating back \< 5 years (exceptions: in situ cervical carcinoma, appropriately treated basal cell carcinoma of the skin)~4. Severe secondary internal diseases, including uncontrolled diabetes mellitus or an acute infection~5. Concomitant medication or planned treatment with strong CYP450 3A4/5 inducers or inhibitors (list of medicinal products in the appendix) or the relevant medicinal products were not discontinued a minimum of one week before treatment~6. Peripheral polyneuropathy \> NCI grade II~7. Severe hepatic impairment (AST/ALT \> 2.5 x ULN, , bilirubin \> 1 x ULN)~8. Chronic inflammatory bowel disease~9. Participation in another study~10. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabazitaxel (Type: EXPERIMENTAL): Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22

Based on this trial design, predict the completion outcome and termination type (if applicable).